Scholarlink

<p>Super responders refer to a subset of patients with psoriasis who achieve a rapid and good treatment response to biologics. This post-hoc exploratory analysis aimed to compare the efficacy and safety of vunakizumab between super responders and non-super responders of patients with moderate-to-severe plaque psoriasis. This was a post-hoc exploratory analysis of a phase III trial (NCT04839016). Patients with moderate-to-severe plaque psoriasis receiving vunakizumab who achieved and maintained 100% improvement in the psoriasis area severity index (PASI 100) score at week W12/W16 were defined as W12/W16 super responders; those at W24 and W28 were defined as W24/W28 super responders. A total of 461 patients were enrolled; 154 (33.4%) and 224 (48.6%) patients were W12/W16 and W24/W28 super responders. PASI 75/90/100 and static physician’s global assessment 0/1 response rates at most time points were higher in W12/W16 and W24/W28 super responders than corresponding non-super responders (all <i>P</i> &lt; 0.05). Improvement in patient-reported outcomes (PROs) at most time points was better in W12/W16 and W24/W28 super responders than corresponding non-super responders (all <i>P</i> &lt; 0.05). The incidence of any adverse events was not different between super responders and non-super responders (all <i>P</i> &gt; 0.05). After vunakizumab treatment, super responder status is associated with better treatment response and PROs in patients with moderate-to-severe plaque psoriasis, while the safety is not affected by this status.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of vunakizumab between super responders and non-super responders of patients with moderate-to-severe plaque psoriasis: a post-hoc exploratory analysis of a phase III trial

  • 期刊论文

  • 发表日期：

    2026年1月2日

查看全文
  • Ougen Liu,
  • Caixia Kou,
  • Simin Yu,
  • Huizhong Hu,
  • Xiaoxiao Chen,
  • Meiying Jiang,
  • Shifeng Ren

摘要

Super responders refer to a subset of patients with psoriasis who achieve a rapid and good treatment response to biologics. This post-hoc exploratory analysis aimed to compare the efficacy and safety of vunakizumab between super responders and non-super responders of patients with moderate-to-severe plaque psoriasis. This was a post-hoc exploratory analysis of a phase III trial (NCT04839016). Patients with moderate-to-severe plaque psoriasis receiving vunakizumab who achieved and maintained 100% improvement in the psoriasis area severity index (PASI 100) score at week W12/W16 were defined as W12/W16 super responders; those at W24 and W28 were defined as W24/W28 super responders. A total of 461 patients were enrolled; 154 (33.4%) and 224 (48.6%) patients were W12/W16 and W24/W28 super responders. PASI 75/90/100 and static physician’s global assessment 0/1 response rates at most time points were higher in W12/W16 and W24/W28 super responders than corresponding non-super responders (all P < 0.05). Improvement in patient-reported outcomes (PROs) at most time points was better in W12/W16 and W24/W28 super responders than corresponding non-super responders (all P < 0.05). The incidence of any adverse events was not different between super responders and non-super responders (all P > 0.05). After vunakizumab treatment, super responder status is associated with better treatment response and PROs in patients with moderate-to-severe plaque psoriasis, while the safety is not affected by this status.